Alliqua, Inc. | 2013 | FY | 3

The following table summarizes the common stock and warrant offerings during the years ended December 31, 2013 and 2012:
 
 
 
 
 
 
 
 
 
 
 
 
Five-Year Warrants
 
 
 
 
 
 
 
 
 
 
Common
 
Investor
 
Placement Agent
 
 
 
 
Issuance
 
 
Gross
 
Issuance
 
Stock
 
Warrants
 
Warrants
 
Exercise
 
Date
 
 
Proceeds
 
Costs
 
(Shares)
 
(Shares)
 
(Shares)
 
Price
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
02/16/12
 
 
$
1,050,000
 
$
62,975
 
480,000
 
240,000
 
25,360
 
$
3.02
 
08/14/12
[1]
 
 
265,000
 
 
-
 
121,143
 
60,571
 
-
 
$
2.19
 
09/28/12
[2]
 
 
25,000
 
 
-
 
11,429
 
5,714
 
-
 
$
2.19
 
10/11/12
[2]
 
 
5,000
 
 
-
 
2,286
 
1,143
 
-
 
$
2.19
 
11/08/12
[3]
 
 
815,000
[4]
 
24,500
 
372,572
 
372,572
[5]
8,000
[5]
$
2.19
 
2012 Total
 
 
 
2,160,000
 
 
87,475
 
987,430
 
680,000
 
33,360
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
02/22/13
 
 
 
380,500
 
 
-
 
107,372
 
107,372
 
-
 
$
4.24
 
04/11/13
 
 
 
236,000
 
 
37,100
 
66,596
 
66,596
 
6,660
 
$
4.24
 
04/22/13
 
 
 
576,000
 
 
55,100
 
162,540
 
162,540
 
13,150
 
$
4.24
 
05/31/13
 
 
 
288,000
 
 
31,300
 
81,270
 
81,270
 
8,127
 
$
4.24
 
06/28/13
 
 
 
1,976,925
 
 
62,632
 
557,862
 
557,862
 
17,674
 
$
4.24
 
11/14/13
 
 
 
6,000,000
[6]
 
-
 
1,672,474
 
836,237
 
-
 
$
5.69
 
11/18/13
 
 
 
7,000,000
 
 
494,000
 
1,951,220
 
975,610
 
136,490
 
$
5.69
 
2013 Total
 
 
 
16,457,425
 
 
680,132
 
4,599,334
 
2,787,487
 
182,101
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total
 
 
$
18,617,425
 
$
767,607
 
5,586,764
 
3,467,487
 
215,461
 
 
 
 
 
[1]
Includes 86,857 shares of common stock and five-year warrants to purchase 43,429 shares of common stock at an exercise price of $2.19 per share issued to certain officers and members of the Board of Directors in exchange for gross proceeds of $190,000.
[2]
Issued to a member of the Board of Directors.
[3]
Includes 89,143 shares of common stock and five-year warrants to purchase 89,143 shares of common stock at an exercise price of $2.19 per share issued to certain members of the Board of Directors for gross proceeds of $195,000.
[4]
Includes $50,000 represented by the conversion of debt.
[5]
See Note 15 – Fair Value Measurement for details regarding the fair value of the warrant liability recorded in connection with these issued warrants.
[6]
See Note 9 – Commitment and Contingencies for details regarding the Celgene License, Marketing, and Development Agreement and Supply Agreement.

us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock